Business
Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform
ROCKVILLE, Md., Sept. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty
About this update from Shuttle Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"ROCKVILLE, Md., Sept. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase (HDAC) inhibitor platform technology titled \"Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated (ATM) Activation and Methods of Use Thereof.\"\n\n \n \n \n \n \n \n\n \nHDAC inhibitors have been described as \"a novel class of drugs that target enzymes involved in regulation of critical cellular functions that can inhibit cancer growth and activate cellular immunity,\" according to Scott Grindrod, PhD, lead inventor and Laboratory Director at Shuttle Pharmaceuticals.\nThe Company's HDAC pre-clinical inhibitor platform includes:\nSP-2-225 is Shuttle Pharma's pre-clinical Class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6. SP-2-225 has effects on the regulation of the immune system. The interactions of radiation therapy with the immune response to cancers are of great current interest, offering insight into potential mechanisms for primary site and metastatic cancer treatment. For this reason, Shuttle Pharma selected SP-2-225 as the candidate lead HDAC inhibitor for preclinical development. Shuttle Pharma is advancing drug manufacture and IND-enabling studies with the goal of enabling a Phase I clinical trial in 2024. With the introduction of check-point inhibitors, CAR-T therapies and personalized medicine in cancer, regulation of the immune response following RT continues to be of significant clinical and commercial interest.SP-1-161 is Shuttle Pharma's pre-clinical candidate lead HDAC inhibitor, radiation sensitizing candidate product. This pan HDAC inhibitor initiates the mutated ataxia-telangiectasia response pathway. Using rational drug design, Shuttle Pharma discovered HDAC inhibitors and ATM activators capable of radiation sensitizing cancer cells and protecting normal cells. The candidate drug may serve as a direct chemotherapeutic agent or as a radiation sensitizer for treating cancers. In preclinical studies, SP-1-161 protected normal breast epithelial cells (184A1) following e...